Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Vaxxinity, Inc. (VAXX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.9900+0.0100 (+0.51%)
At close: 04:00PM EST
1.9800 -0.01 (-0.50%)
After hours: 07:45PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close1.9800
Open1.9300
Bid1.9100 x 800
Ask1.9300 x 1100
Day's Range1.7300 - 1.9900
52 Week Range1.2600 - 10.5700
Volume367,400
Avg. Volume352,185
Market Cap250.851M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.3580
Earnings DateNov 10, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for VAXX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Vaxxinity, Inc.
    Daily – Vickers Top Buyers & Sellers for 01/07/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    11 months agoArgus Research
View more
  • GlobeNewswire

    Vaxxinity Announces Positive Topline Pivotal Phase 3 COVID-19 Booster Data for UB-612

    Vaxxinity’s next-generation COVID-19 booster candidate UB-612 achieves primary and key secondary immunogenicity endpoints in a pivotal head-to-head heterologous booster trial against three authorized vaccine platforms: mRNA (Pfizer-BioNTech’s BNT162b2), adenovirus vector (AstraZeneca’s ChAdOx1-S), and inactivated virus (Sinopharm’s BIBP) UB-612 elicits superior neutralizing antibody titers and seroconversion rates against both Wuhan and Omicron BA.5 variants compared to adenovirus vector (ChAdOx

  • Motley Fool

    Why Shares of Vaxxinity Soared This Week

    Positive news regarding a different company's Alzheimer's treatment may have helped Vaxxinity.

  • GlobeNewswire

    Vaxxinity Reports Third Quarter 2022 Financial Results and Provides Corporate Update

    Phase 1 Part B End-of-Treatment Data Show UB-312 is Well Tolerated and Immunogenic in Parkinson’s Disease Patients VXX-401 Anti-PCSK9 Candidate Demonstrates Durable LDL Cholesterol Lowering in Non-Human Primates UB-612 COVID-19 Vaccine Completes Enrollment in Pivotal Phase 3 Heterologous Booster Clinical Trial; Rolling Submission for Conditional/Provisional Authorization Initiated in UK & Australia Vaxxinity Hosting Analyst and R&D Day with Live Webcast Today at 8:30 a.m. ET DALLAS, Nov. 10, 202

Advertisement
Advertisement